PMV Pharmaceuticals, Inc. (PMVP)
| Market Cap | 68.79M +32.4% |
| Revenue (ttm) | n/a |
| Net Income | -78.34M |
| EPS | -1.48 |
| Shares Out | 53.33M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 972,852 |
| Open | 1.400 |
| Previous Close | 1.420 |
| Day's Range | 1.290 - 1.420 |
| 52-Week Range | 0.810 - 1.880 |
| Beta | 1.41 |
| Analysts | Buy |
| Price Target | 5.00 (+287.6%) |
| Earnings Date | May 12, 2026 |
About PMVP
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for PMVP stock is "Buy" and the 12-month stock price target is $5.0.
News
PMV Pharmaceuticals price target lowered to $5 from $6 at Oppenheimer
Oppenheimer lowered the firm’s price target on PMV Pharmaceuticals (PMVP) to $5 from $6 and keeps an Outperform rating on the shares following quarterly results and business update. Rezatapopt continu...
PMV Pharmaceuticals reports Q1 EPS (34c), consensus (38c)
“The first quarter was one of continued execution as we advance the PYNNACLE study and remain on track to target an NDA submission for rezatapopt for platinum-resistant/refractory ovarian cancer in…
PMV Pharmaceuticals chair Rich Heyman to depart, Laurie Stelzer to succeed
PMV Pharmaceuticals (PMVP) announced a transition on its board of directors. Laurie Stelzer, who has served as a member of the board since 2020, has been appointed chair of the…
PMV Pharmaceuticals Announces Board Chair Transition
Rich Heyman to retire from PMV Pharma Board of Directors; Laurie Stelzer, Director since 2020, appointed as new Chair Rich Heyman to retire from PMV Pharma Board of Directors; Laurie Stelzer, Director...
PMV Pharmaceuticals price target lowered to $4 from $16 at Evercore ISI
Evercore ISI lowered the firm’s price target on PMV Pharmaceuticals (PMVP) to $4 from $16 and keeps an Outperform rating on the shares. The firm updated models among its small-to-mid…
PMV Pharmaceuticals reports FY25 EPS ($1.48), consensus ($1.51)
“2025 was an important and productive year for PMV Pharma as we reported positive Phase 2 interim data from the registrational PYNNACLE clinical trial and made significant progress in enrolling…
PMV Pharmaceuticals sees cash runway to end of 2Q27
As of December 31, 2025, PMV Pharma had $112.9 million in cash, cash equivalents, and marketable securities, compared to $183.3 million at December 31, 2024. Net cash used in operations…
PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights
PRINCETON, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of sm...
PMV Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
Rezatapopt demonstrates strong efficacy and safety in heavily pretreated ovarian cancer, with a 46% ORR and 8-month median DOR. NDA submission is planned for Q1 2027, with global expansion and combination studies underway. US market potential is estimated at $350–$420 million.
PMV Pharmaceuticals announces results of Phase 1 trial of rezatapopt in NEJM
PMV Pharmaceuticals (PMVP) announced that results from the Phase 1, first-in-human portion of the ongoing Phase 1/2 PYNNACLE study evaluating rezatapopt in patients with advanced solid tumors harborin...
PMV Pharmaceuticals reports Q3 EPS (40c), consensus (40c)
“I am incredibly proud of our team and their commitment to rapidly and efficiently advancing the PYNNACLE study,” said David Mack, Ph.D., President and Chief Executive Officer of PMV Pharma.
PMV Pharmaceuticals announces updated rezatapopt monotherapy interim data
PMV Pharmaceuticals (PMVP) announced updated data from the Phase 2 pivotal portion of the ongoing PYNNACLE clinical trial. Results were presented in an oral presentation by Alison M. Schram, M.D.,…
PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
PRINCETON, N.J., Oct. 24, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of sma...
PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
PRINCETON, N.J., Oct. 13, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of sma...
PMV Pharmaceuticals announces interim data from Phase 2 portion of PYNNACLE
PMV Pharmaceuticals (PMVP) announced interim data from the Phase 2 pivotal portion of the PYNNACLE clinical trial. The ongoing Phase 1/2 PYNNACLE clinical trial is evaluating rezatapopt in patients wi...
PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
PRINCETON, N.J., Sept. 10, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of sm...
PMV Pharmaceuticals reports Q2 EPS (41c), consensus (38c)
Cash, cash equivalents, and marketable securities of $148.3 million as of June 30, 2025, providing expected cash runway to end of 2026. “Our team has continued to execute at an…
PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights
PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of sma...
PMV Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025
The company is advancing Rezatapopt, targeting the TP53 Y220C mutation, through a phase II basket study with ovarian cancer as the anchor. Interim data from 50 patients is expected mid-2025, with NDA submission planned for late 2026. Cash reserves support operations through this period.
PMV Pharmaceuticals Transcript: TD Cowen's 6th Annual Oncology Innovation Summit
The pivotal phase II trial is on track, with interim data for 50 patients expected in July or August, focusing on ovarian and other solid tumors. Regulatory strategy allows for either ovarian-only or tumor-agnostic filing, and cash reserves support operations through 2026.
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences
PRINCETON, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor...
PMV Pharmaceuticals reports Q1 EPS (34c), consensus (38c)
“Our registrational PYNNACLE trial continues to progress well and enrollment remains on track,” said David Mack, Ph.D., President and Chief Executive Officer of PMV Pharma. “I am very appreciative of…
PMV Pharmaceuticals sees cash runway to end of 2026
PMV Pharma ended the first quarter with $165.8 million in cash, cash equivalents, and marketable securities, compared to $183.3 million as of December 31, 2024. Net cash used in operations…
PMV Pharmaceuticals Transcript: TD Cowen 45th Annual Healthcare Conference
Rezatapopt, a first-in-class p53 reactivator, is in a pivotal Phase II trial for TP53 Y220C mutant solid tumors, with interim analysis mid-2024 and NDA submission targeted for end of 2026. The program shows promising efficacy and safety, with global expansion and new pipeline candidates underway.
PMV Pharmaceuticals sees cash runway to end of 2026
As of December 31, 2024, PMV Pharma had $183.3 million in cash, cash equivalents, and marketable securities, compared to $228.6 million at December 31, 2023. Net cash used in operations…